Hong Kong's new home prices sink as SHKP launches at 11-year low in Sai Kung
Advertisement
The developer launched the price list for 158 of the 781 units at its Sierra Sea, Phase 1A (2) at HK$10,398 per square foot on average, according to property agents. The units represent the first batch of its 9,700-unit Sai Sha development in Shap Sze Heung, which is located between Sai Kung and Ma On Shan.
This would be Hong Kong's single largest property project by a developer since the 15,808 homes at Kingswood Villas in Tin Shui Wai developed by Cheung Kong Property between 1991 and 1999. Cheung Kong was renamed CK Asset Holdings in August 2017.
'The pricing is extremely shocking,' said Sammy Po Siu-ming, CEO of Midland Realty's residential division. 'The average price per square foot is the lowest in about 11 years in Ma On Shan, [possibly] to capture the market focus.'
Financial Secretary Paul Chan Mo-po leads a delegation of Beijing officials to view the plans for Northern Metropolis in November 2024. Photo: Handout
The first batch comprises three one-bedroom units, 118 two-bedrooms units and 37 three-bedrooms flats, with saleable area ranging from 301 to 574 sq ft. These units were priced between HK$9,499 and HK$11,126 per square foot. All the units were priced under HK$6 million (US$773,400) each, with the cheapest at HK$2.99 million after discounts. Sales will begin next week.
Advertisement
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
8 hours ago
- South China Morning Post
US-India trade talks seen unlikely to produce deal by August 1 deadline
Months of intense negotiations appear unlikely to produce a trade deal between the US and India before the August 1 deadline, despite US President Donald Trump having teased one for months as 'coming soon', according to three people familiar with the situation. One person described the current state of discussions as a 'total mess' behind the scenes as Trump and his trade representative, Jameison Greer, continue to push for a pact that would secure greater market access for American produce, dairy, and poultry in India. 'Despite bullish comments by India's trade minister, securing a deal by August 1 seems nearly impossible', said Rick Rossow, chair in US-India Policy Studies at the Center for Strategic and International Studies, a Washington think tank. He said that while 'negotiations seemed to move pretty fast in the early days', the closing stages are 'always the most difficult'. Indian Minister of State for External Affairs Kirti Vardhan Singh on Thursday told the Indian Parliament that negotiations with the US were 'active' and revolved around 'enhanced mutual market access, reduction of tariffs and non-tariff barriers and closer integration of supply chains'. Rajesh Agarwal, India's chief negotiator and Commerce Department special secretary, was in Washington last week for trade talks but the July 14-17 negotiation ended without any announcement.
RTHK
15 hours ago
- RTHK
DSE candidates face 4pc rise in fees for 2026 exams
DSE candidates face 4pc rise in fees for 2026 exams The HKEAA says fees and charges are going up to optimise use of resources and maintain its long-term stability. File photo: RTHK The exams body on Friday announced a 4 percent increase in fees for the 2026 Hong Kong Diploma of Secondary Education (HKDSE) exams and the introduction of a new fees structure for private candidates. According to the Hong Kong Examinations and Assessment Authority (HKEAA), the fees for school candidates for key language and other subjects have been raised by HK$30 and HK$20 each respectively. For a candidate taking six subjects – two language and four other subjects – the total fees will amount to HK3,630. The HKEAA stated that the hike is similar to previous years and remains at a relatively moderate level, with the adjustment taking into account various factors. For private candidates, a flat fee of HK$595 will be charged and there will be a new two-tier fees structure depending on their residency status. Candidates who are non-Hong Kong permanent residents are required to pay HK$1,377 for each language subject and HK$1,119 for each additional subject, HK$600 more when compared with that for local residents. For non-permanent residents who are under 18 years old and sitting the exam for the first time, there will be a new special entry fee of HK$2,000 per person. That would mean examination fees of more than HK$9,800 for those taking four core subjects and two electives. The HKEAA said the fees and charges had been revised to optimise the use of resources and maintain the long-term financial stability of the body. "There has been a notable increase in the number of private candidates in recent years. Some of these candidates, holding non-HKDSE qualifications, are required to submit Special Entry applications, which necessitate substantial manpower and resources from the authority to carefully vet each case," it said. "Additional examination centres and personnel have also been arranged to accommodate the growing number of private candidates, further increasing the operational costs of the HKDSE."
South China Morning Post
16 hours ago
- South China Morning Post
Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of their agreement, Pfizer will also pay 3SBio up to US$150 million to solely develop and commercialise SSGJ-707 within the mainland, the two companies said on Thursday. Pfizer also agreed to buy 31.1 million new shares in S3Bio, or a 1.3 per cent equity stake, for HK$785 million, according to a stock exchange filing. The deal at HK$25.2055 per share represents a 17 per cent discount to its market price on Thursday. 3SBio's shares fell 6.41 per cent to HK$28.45 on Friday. The transaction reflected the strong momentum of Chinese biotech firms in the field of drugs research and the increased interest from major foreign pharmaceutical companies to license their intellectual property.
